OrbiMed’s Post

From empirical to data-driven, our patent allows us to help new cancer patients to find existing cases of unprecedentedly similarity, and use their historical performance to evaluate all existing treatment options statistically. It is a revolution in cancer diagnostics globally. The key message of our patent (US and China pending) is to use the combination of the quantitated protein biomarkers as the "fingerprint" of a cancer patient, so we can develop a super big (>50,000) database of existing cases, indexed by the "fingerprint". All new patients can find similar existing cases by their "fingerprint" as well as other diagnostic factors to learn from the success and mistakes of these existing cases in day clinical practice. It will be, and it should be, the standard cancer diagnostics in daily practice globally.

Lamassu BioTech, a cutting-edge biotech company dedicated to innovative cancer therapies, has been awarded a grant from the The National Institutes of Health and National Cancer Institute (NCI) for the development of their groundbreaking treatment for p53 wild-type sarcomas. The project focuses on advancing SA53, a novel therapeutic that targets p53 wild-type sarcomas, malignant tumors of connective or non-epithelial tissue. SA53 has demonstrated remarkable potency, efficacy and safety in preclinical models, positioning it for an Investigational New Drug (IND) submission. This innovative approach offers promising prospects for addressing chemo-resistant cancer and presents a significant pathway for advancing cancer care. Read more here: https://lnkd.in/dWCkg6Ya

Today we announced that an abstract was accepted for poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Title: Interleukin (IL)-15 and IL-21 synergistically enhance NK and CD8+ T cell responses Presenting Author: Phoi Tiet, Senior Research Associate, Equillium, Inc. Abstract Number: 908 Location: Exhibit Halls A & B Date: Saturday, November 9, 2024 The abstract highlights that cytokines are a focus of anti-cancer therapeutic development due to their central role in regulating anti-tumoral immune responses, and that data demonstrates that IL-15 and IL-21 synergistically augment NK and CD8 T cells activities, which further enhanced their proliferation and cytolytic function. With the ability to rescue T cell dysfunction, this cytokine combination could be a promising treatment approach to stimulating anti-tumor immune responses.

🔬 **Elevate Cancer Diagnostics with BioGenex’s PRAME Antibody** 🔬 BioGenex is transforming cancer diagnostics with our PRAME antibody, a key biomarker for skin tumors and various malignancies including melanoma, lung, breast, and renal cancers. 🧬 **Why PRAME?** - Essential for assessing metastasis risk. - Broad application across numerous cancers. - Minimal expression in normal tissues. 🔍 **Our Offering** We provide ready-to-use and concentrated Skin & Melanoma Tumor Panel Markers for both manual and automated systems, crucial for clinical diagnostics and drug discovery. 🌐 **Advance with Us** Explore the potential of our PRAME antibody and join us in refining cancer diagnostics for better treatment outcomes. Learn More: https://hubs.la/Q02mbSBl0 #CancerDiagnostics #PRAME #BioGenex #OncologyInnovation ---

This morning, we published a press release announcing the encouraging key conclusions for the updated survival analysis from our Phase 2 C-02 trial in advanced cervical cancer. The analysis highlights the extended benefit beyond what would be expected based on historical data testing atezolizumab (Tecentriq®) as monotherapy.   🌟Key highlights:🌟   *The latest data analysis closely mirrors our previous findings, now with a minimum observation period of 24 months for the remaining patients, providing a more robust basis compared to the earlier 12-month timeframe. *The promising outcomes from the C-02 trial support the accelerated development pathway for VB10.16. This includes moving forward with the anticipated pivotal trial in the U.S., C-04, focused on recurrent or metastatic cervical cancer. *Encouraged by these results, we're not just limiting ourselves to cervical cancer. Plans and activities are in motion to expand the use of VB10.16 into earlier treatment stages and to explore its potential in battling head and neck cancers.   🔗 To dive deeper into these groundbreaking findings, read our press release here https://lnkd.in/eGpPHxkr.    Our journey towards redefining cancer treatment continues, and today's update marks a significant milestone in our pursuit. Stay connected with us as we advance towards making a substantial difference in the lives of those affected by cancer.   #CancerResearch #ClinicalTrials #Innovation #CervicalCancer #Oncology

November is Lung Cancer Awareness Month #LCAM 🤍🫁 💡 Did you know that early detection and prompt treatment are crucial for lung cancer patients? Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*. IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️ Learn more 👉🏻 https://lnkd.in/enNpBhir #Biocartis #Idylla #EGFR #GeneFusion #ALK #ROS1 #RET #METex14 #LungCancerAwarenessMonth #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

📢 Breaking News! Exeliom is proud to announce the launch of three phase II clinical trials in immuno-oncology, marking a significant milestone in the fight against cancer. Our lead candidate, EXL01, will be evaluated in gastric cancer, NSCLC, and hepatocellular carcinoma, in collaboration GERCOR, CHU de Lille, and Centre Eugène Marquis of Rennes. EXL01, the first-ever single-strain Live Biotherapeutic Product (LBP) utilizing Faecalibacterium prausnitzii, holds promise as an adjuvant to immune checkpoint inhibitors, potentially revolutionizing cancer treatment outcomes. These trials aim to address the unmet medical needs of patients with poor prognosis, with results expected by the end of 2026. Positive outcomes could pave the way for phase III studies. 🔗 https://lnkd.in/e26ksZ7q #ImmunoOncology #CancerResearch #ClinicalTrials #Immunotherapy #Inflammation

#ESMOBreast24: Have a look at what experts such as Suzette Delaloge, Evandro de Azambuja, Carmen Criscitiello, fabrice andre, Mafalda Oliveira and Erika Hamilton have to say to entice you to attend this event. ⏲️ Early registration deadline: 6 March 2024 🔗https://ow.ly/NFTO50QH4SR During this event, you will be able to: ➡️ Understand recent developments in novel diagnostics, biomarkers and treatments in breast cancer ➡️ Be updated on the rapid development of novel antibody drug conjugates for breast cancer ➡️ Gain insights on new strategies for Luminal, HER2 positive, HER2-low and triple negative breast cancer ➡️ Understand special considerations for different subgroups of patients with breast cancer

🔬 New Research Alert! published in #DrugDevIndPharm. 🌟 Synergistic effects of quercetin-loaded CoFe2O4@Liposomes regulate DNA damage and apoptosis in MCF-7 cancer cells: based on biophysical magnetic hyperthermia 🌟 The study explores the development and application of quercetin-loaded magnetoliposomes (Que-MLs) for breast cancer treatment. The study demonstrates that these Que-MLs, when subjected to magnetic hyperthermia (MHT), significantly enhance the cytotoxic effects on MCF-7 breast cancer cells. The encapsulation of quercetin in CoFe2O4 liposomes improves drug delivery efficiency, leading to increased DNA damage and apoptosis in cancer cells. The research highlights the potential of combining chemotherapy with magnetic hyperthermia to achieve a more effective and targeted cancer treatment. 📖 Read the full article here: https://lnkd.in/gqh55Jw6 #CancerResearch #DrugDelivery #Liposomes #BreastCancer